Stock 603858 SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Shandong Buchang Pharmaceuticals Co., Ltd.

Equities

603858

CNE100002FV6

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-07-16 pm EDT 		5-day change 1st Jan Change
15.08 CNY +0.13% Intraday chart for Shandong Buchang Pharmaceuticals Co., Ltd. -0.07% -11.35%
Jun. 15 Shandong Buchang Pharmaceuticals Co., Ltd. announces an Increase in Equity Buyback. CI
May. 29 Shandong Buchang Pharmaceuticals Gets China Nod for Cholesterol Control Tablets MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Shandong Buchang Pharmaceuticals Co., Ltd. announces an Increase in Equity Buyback.
Shandong Buchang Pharmaceuticals Gets China Nod for Cholesterol Control Tablets
Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Buchang Pharma Obtains Green Light to Trial Gastric Cancer Drug Combination
Buchang Pharma’s Drugs Retain National Medical Insurance Coverage
Shandong Buchang Pharmaceuticals Co., Ltd. announces an Equity Buyback for CNY 360 million worth of its shares.
Shandong Buchang Pharmaceuticals Co., Ltd. authorizes a Buyback Plan.
Buchang Pharma's Unit Gets Nod to Test Colorectal Cancer Drug
Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Buchang Pharma Unit Gets Nod to Trial Cancer Treatment
Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Selling Expenses of Chinese Listed Pharma Companies About 1.5x Higher Than Net Profits in 2022
Buchang Pharmaceuticals to Set Up Medical Device Subsidiary
Buchang Pharma Unit Gets Nod to Make Amendments to Diabetes Drug
Buchang Pharmaceuticals to Invest 223 Million Yuan Into Old Factory Upgrade
Buchang Pharma's Unit Passes Regulator's Good Manufacturing Practice Evaluation
Buchang Pharma Unit Passes Regulatory Inspection
Buchang Pharma Unit Gets Nod for Flu Vaccine Trials in China
Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 603858 Stock
  4. News Shandong Buchang Pharmaceuticals Co., Ltd.
  5. Other languages